Bloom Burton Has Negative Outlook of TSE:MBX FY2025 Earnings

Microbix Biosystems Inc. (TSE:MBX) – Stock analysts at Bloom Burton dropped their FY2025 earnings per share estimates for Microbix Biosystems in a research note issued on Wednesday, April 9th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per share of $0.01 for the year, down from their previous estimate of $0.03. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share.

Microbix Biosystems Price Performance

Shares of TSE:MBX opened at C$0.36 on Monday. The company has a quick ratio of 5.57, a current ratio of 7.15 and a debt-to-equity ratio of 22.61. The business has a 50 day moving average price of C$0.43 and a 200 day moving average price of C$0.39. The company has a market cap of C$46.76 million, a price-to-earnings ratio of 13.52 and a beta of 0.34. Microbix Biosystems has a twelve month low of C$0.29 and a twelve month high of C$0.55.

Insider Activity

In related news, Senior Officer Mark Adrian Luscher sold 70,750 shares of Microbix Biosystems stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of C$0.43, for a total transaction of C$30,295.15. Also, Director Cameron Lionel Groome sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of C$0.43, for a total value of C$86,500.00. Over the last three months, insiders sold 476,750 shares of company stock valued at $213,995. 14.00% of the stock is owned by company insiders.

Microbix Biosystems Company Profile

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.